Schizophrenia Clinical Trials in New York

Showing 181-187 of 187 trials

Guanfacine Adjunctive Treatment to Atypical Antipsychotics for Cognitive Dysfunction in Schizophrenia

NCT00469664

Our overall aim is to determine if the administration of guanfacine in combination with aripiprazole, olanzapine, quetiapine, and/or risperidone is significantly more effective than any of those medications alone in treating some of the cognitive impairment in schizophrenia.

SchizophreniaSchizoaffective DisorderCognitive Impairment

Research Foundation for Mental Hygiene, Inc.50 participantsStarted Feb 2000

New York, New York, United States • The Bronx, New York, United States • W. Brentwood, New York, United States

COMPLETEDPhase 4< 1 mile

Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder

NCT00090012

The purposes of this study are to determine: * The effectiveness of olanzapine as compared to quetiapine in treating and preventing the recurrence of a variety of symptoms of schizophrenia and schizoaffective disorder in patients who are obese or overweight. * The safety of olanzapine as compared to quetiapine.

SchizophreniaSchizoaffective Disorder

Eli Lilly and Company340 participantsStarted Jul 2004

Garden Grove, California, United States • La Mesa, California, United States • San Diego, California, United States +22 more locations

Guanfacine Adjunctive Treatment to Atypical Antipsychotics for Cognitive Dysfunction in Schizophrenia

Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder

Schizophrenia Trials in Other Cities

Olanzapine Versus Placebo in the Treatment of Adolescents With Schizophrenia

A Combination of Two Currently Approved Drugs to Enhance the Treatment of Schizophrenia

Effect of High-Dose B-Complex Vitamins on the Symptoms of Schizophrenia

Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety

The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder

Other Conditions in New York